CN Patent

CN1404470A — 2－氧代－1－吡咯烷衍生物、其制备方法和用途

Assigned to UCB Farchim SA · Expires 2003-03-19 · 23y expired

What this patent protects

本发明涉及2－氧代－1－吡咯烷衍生物及其制备方法和用途，本发明还涉及一种从不饱和的2－氧代－1－吡咯烷衍生物出发制备α－乙基－2－氧代－1－吡咯烷乙酰胺衍生物的方法。具体地，本发明涉及新的中间体及其在制备S－α－乙基－2－氧代－1－吡咯烷乙酰胺的方法中的用途。

USPTO Abstract

本发明涉及2－氧代－1－吡咯烷衍生物及其制备方法和用途，本发明还涉及一种从不饱和的2－氧代－1－吡咯烷衍生物出发制备α－乙基－2－氧代－1－吡咯烷乙酰胺衍生物的方法。具体地，本发明涉及新的中间体及其在制备S－α－乙基－2－氧代－1－吡咯烷乙酰胺的方法中的用途。

Drugs covered by this patent

Briviact (BRIVARACETAM) · UCB

Patent Metadata

Patent number: CN1404470A
Jurisdiction: CN
Classification: —
Expires: 2003-03-19
Drug substance claim: No
Drug product claim: No
Assignee: UCB Farchim SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.